Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -11386.31% is 268% below its 5-year average of -3093.11%, around the middle of its 5-year range (-59209.38%–13250.57%).
146.73% below its 12-month average of -4614.91%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2799.32%.
EBITDA MARGIN
-11386.31%
EBITDA MARGIN AVG TTM
-4614.91%
EBITDA MARGIN AVG 3Y
-12938.11%
EBITDA MARGIN AVG 5Y
-3093.11%
EBITDA MARGIN AVG 10Y
-843.75%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-146.73%
CURRENT VS 3Y AVG
+11.99%
CURRENT VS 5Y AVG
-268.12%
CURRENT VS 10Y AVG
-1249.49%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Seres Therapeutics, Inc.
Market Cap
$27.28M
EBITDA Margin
-11386.31%
TTM Avg
-4614.91%
3Y Avg
-12938.11%
5Y Avg
-3093.11%
Market Cap
$26.46M
EBITDA Margin
-989.17%
TTM Avg
-572.43%
3Y Avg
-292.90%
5Y Avg
-228.52%
Market Cap
$28.14M
EBITDA Margin
-40038.95%
TTM Avg
-34141.60%
3Y Avg
-20873.74%
5Y Avg
-16727.01%
Market Cap
$26.19M
EBITDA Margin
-541.66%
TTM Avg
-507.83%
3Y Avg
-427.73%
5Y Avg
-407.72%
Market Cap
$28.87M
EBITDA Margin
-706.55%
TTM Avg
-1095.73%
3Y Avg
-881.72%
5Y Avg
-688.00%
Market Cap
$29.60M
EBITDA Margin
-2299.40%
TTM Avg
-2138.43%
3Y Avg
-3018.63%
5Y Avg
-2749.35%
Market Cap
$29.63M
EBITDA Margin
-17954.61%
TTM Avg
-17954.61%
3Y Avg
-17954.61%
5Y Avg
-17954.61%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | $27.28M | -11386.31% | -4614.91% | -12938.11% | -3093.11% |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $27.15M | N/A | N/A | N/A | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $26.46M | -989.17% | -572.43% | -292.90% | -228.52% |
| aTyr Pharma, Inc. (ATYR)vs › | $28.14M | -40038.95% | -34141.60% | -20873.74% | -16727.01% |
| InspireMD, Inc. (NSPR)vs › | $26.19M | -541.66% | -507.83% | -427.73% | -407.72% |
| OneMedNet Corporation (ONMD)vs › | $28.87M | -706.55% | -1095.73% | -881.72% | -688.00% |
| Quantum Cyber N.V. (QUCY)vs › | $29.60M | -2299.40% | -2138.43% | -3018.63% | -2749.35% |
| Context Therapeutics Inc. (CNTX)vs › | $29.60M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.63M | -17954.61% | -17954.61% | -17954.61% | -17954.61% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.54M | -710238.40% | -369696.29% | -185511.92% | -193923.76% |
Gross Margin
-423.8%
EBITDA Margin
-11386.3%
Operating Margin
-11910.1%
Net Margin
-1192.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2799.32% |
| 2026-03-31 | -5621.79% |
| 2025-12-31 | -3936.53% |
| 2025-09-30 | -6101.99% |
| 2023-12-31 | -59209.38% |
| 2023-06-30 | 40.37% |
| 2023-03-31 | 13250.57% |
| 2022-12-31 | -6838.97% |
| 2022-09-30 | -1665.51% |
| 2022-06-30 | -5069.08% |
| 2022-03-31 | -3629.00% |
| 2021-12-31 | -663.07% |
| 2021-09-30 | 55.16% |
| 2021-06-30 | -887.63% |
| 2021-03-31 | -591.99% |
| 2020-12-31 | -93.31% |
| 2020-09-30 | -2005.58% |
| 2020-06-30 | -311.89% |
| 2020-03-31 | -218.46% |
| 2019-12-31 | -228.18% |
| 2019-09-30 | -217.71% |
| 2019-06-30 | -76.31% |
| 2019-03-31 | -300.67% |
| 2018-12-31 | -185.14% |
| 2018-09-30 | -223.49% |
| 2018-06-30 | -567.69% |
| 2018-03-31 | -662.93% |
| 2017-12-31 | -912.04% |
| 2017-09-30 | -23.67% |
| 2017-06-30 | -884.41% |
| 2017-03-31 | -801.33% |
| 2016-12-31 | -789.82% |
| 2016-09-30 | -137.10% |
| 2016-06-30 | -907.66% |
| 2016-03-31 | -720.66% |
